Provid to Acquire Tripos Discovery Research
Posted on: Friday, 5 January 2007, 18:00 CST
NORTH BRUNSWICK, N.J., Jan. 5 /PRNewswire/ -- Provid Pharmaceuticals Inc. is pleased to announce that it has signed a definitive agreement to acquire Tripos Discovery Research (TDR), the UK-based drug discovery division of Tripos, Inc. Provid's management and scientific leadership team believes that a shared future with TDR will allow it to deliver expert medicinal chemistry and drug discovery services to the biotech, academic, and pharmaceutical communities.
It is Provid's intention that the LeadQuest libraries, LeadDiscovery platform, and other product and service offerings from TDR will continue to be made available to customers, and will be continually evolved to serve newly recognized opportunities. Provid will continue to offer expert collaborative research services to the biotech, academic, and pharmaceutical community. Provid has exceptional capabilities in medicinal chemistry, structure-based drug design, and lead optimization, as well as protein biochemistry and assay development. Provid is also recognized as a world leader in peptide mimetics technology.
"The mission of the company centers on chemistry-based drug discovery as the key to unlock the value of biological targets for Provid's customers and collaborators. Invention and design require high technology expertise and experience in the art of medicinal chemistry. These are highly developed within the expanded company," said Gary Olson, President and Chief Scientific Officer of Provid. "The combined entity will have the capability to pursue all aspects of drug discovery -- from target, to hit, to lead, to development candidate. Furthermore, the integration of the capabilities of each organization will give current customers continuity for their ongoing projects in drug design and discovery, and afford unique and exceptional tools and approaches for the future."
The transaction is expected to close in the first quarter of 2007, and is subject to numerous customary terms and conditions, including Provid securing acquisition financing. Further details are outlined in Tripos' press release, which can be found at http://www.tripos.com/. Additional information on the companies is available at http://www.providpharma.com/ and http://www.triposdiscoveryresearch.com/.
For more information visit: http://www.providpharma.com/. Contact: Edwin J. Thomas Chief Financial Officer Provid Pharmaceuticals Inc. 671 US Route 1 North Brunswick, NJ 08902 732-565-1101 x 620 edwin.thomas@providpharma.com
Provid Pharmaceuticals Inc.
CONTACT: Edwin J. Thomas, Chief Financial Officer of ProvidPharmaceuticals Inc., +1-732-565-1101 x620, edwin.thomas@providpharma.com
Web site: http://www.providpharma.com/http://www.tripos.com/
Source: PRNewswire
Related Articles
- Indiana Drug Card to Provide Free Drug Cards to Residents
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- Ramsell Public Health Rx Partners With HealthTrans(R) to Provide Free Drug Discount Program to Public Health Program Participants
- Mexico Pharmaceuticals and Healthcare Report Q2 2008 Provides Independent Forecasts and Competitive Intelligence on Mexico's Pharmaceuticals and Healthcare Industry
- Belgium Pharmaceuticals and Healthcare Report Q2 2008 Provides Independent Forecasts and Competitive Intelligence on Belgium's Pharmaceuticals and Healthcare Industry
- New Report Provides Independent Forecasts and Competitive Intelligence on Serbia's Pharmaceuticals and Healthcare Industry
- 2005/2006 Pharmaceutical R&D Statistical Sourcebook Provides the Latest Intelligence on Every Aspect of Pharmaceutical Development
- Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation
- ProlX Pharmaceuticals Designated Corporate Partner in $5.6 Million Grant to Fund Targeted Therapy Cancer Drug Discovery Research
- Hitachi Data Systems Is First Fibre Channel Storage Array Provider to Achieve Microsoft's Simple SAN for Windows Server Designation
 |
 |
User Comments (0)
RSS Feeds